Navigation Links
A new drug treatment to close the window on colon cancer
Date:7/21/2010

Cancer surgery wreaks havoc on a body's immune system and stress hormones exacerbate the problem. As a result, about half of those who undergo surgery for tumor removal experience a recurrence of cancer in the same region or other parts of the body.

A new clinical approach being developed and tested by Tel Aviv University researchers may be the key to making cancer operations more successful. Prof. Shamgar Ben-Eliyahu, head of Tel Aviv University's Department of Psychology, has opened on a new frontier in cancer research: he is recruiting colon cancer patients for a new clinical study which will test a cocktail of drugs to prevent the negative effects of stress responses to surgery. If successful, it will help the immune system maintain its vigor and prevent the occurrence of new tumors.

Prof. Ben-Eliyahu described his method in a recent issue of the Journal of Immunology.

A more competent immune system

Prof. Ben-Eliyahu and other research teams have confirmed that a competent immune system is critical before, during and after surgery for tumor removal. However, stress responses of the body during this period jeopardize immune competence and facilitate tumor metastasis.

Combining two widely-known medications that affect immune and stress responses, Prof. Ben-Eliyahu has developed a formula he hopes will keep an immune system strong and prevent the recurrence of cancer. Already tested in animal models, the compounds will be employed in a clinical trial in Israel, for which Prof. Ben-Eliyahu's team is currently recruiting patients and funds. They hope to have 800 colon cancer patients participate in the trial, due to begin shortly.

Increasing survival 300%

According to Prof. Ben-Eliyahu, the main stress hormones that appear to negatively impact immune system functioning are released before and during surgery. He says that existing generic drugs could block the influence of these hormones, helping the body to better fend off the stressors of surgery.

In animal studies, Prof. Ben-Eliyahu found that by blocking these hormones he could increase long-term post-operative survival rates from cancer by as much as 300 percent. If his new study on human volunteers succeeds, it could set a new paradigm for cancer treatment and post-surgery recovery rates. "In rats and mice it works with great success, really beautifully," says Prof. Ben-Eliyahu.

In the upcoming trial, Prof. Ben-Eliyahu will boost patients' immune systems with his drug cocktail over a 20-day period, before, during and after surgery. The two compounds to be used in the study are a beta-adrenergic antagonist, which is used to treat hypertension and anxiety, and a Cyclooxygenase-2 inhibitor, used against inflammation and pain. Since the two drugs are already widely available and routinely used in the clinical setting, no patents need be filed for the application of these drugs.


'/>"/>

Contact: George Hunka
ghunka@aftau.org
212-742-9070
American Friends of Tel Aviv University
Source:Eurekalert  

Related medicine news :

1. Improved treatment access requires end to portrayal of drug abusers as already dead
2. Writing checks that bounce: World continues to backtrack on HIV treatment
3. HIV/AIDS treatment curbs spread of disease: UBC-BC CfE study
4. New discovery brings hope to treatment of incurable blood cancer
5. Shoulder arthritis? What patients need to know before treatment
6. Rare Blood Vessel Disease Could Have New Treatment Option
7. NIH awards Scripps Florida scientists $2.3 Million to develop drug addiction treatments
8. New treatment for crippling diabetic Charcot foot
9. Arsenic shows promise as cancer treatment, Stanford study finds
10. Universal HIV testing and immediate treatment could reduce but not eliminate HIV/AIDS epidemic
11. Discovery Opens Door for New Options in Prevention and Treatment of Mesothelioma
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
A new drug treatment to close the window on colon cancer
(Date:2/5/2016)... ... February 05, 2016 , ... The Muscular ... Louisiana Kitchen restaurants, launched the 14th annual “Appetite for a Cure” campaign on ... muscular dystrophy, ALS and related diseases that severely limit strength and mobility. ...
(Date:2/5/2016)... ... February 05, 2016 , ... ... George H. Van Allen have signed a joint enrollment and degree completion agreement. ... pathway toward associate and baccalaureate degrees at FHU|Dickson. , The agreement allows ...
(Date:2/5/2016)... ... February 05, 2016 , ... US Sports Camps ... in Dover, NH to direct high-performance kids yoga training. ChildLight Yoga Studio is centrally ... one hour from Boston. , ChildLight Yoga Studio founder Lisa Flynn expresses her excitement, ...
(Date:2/5/2016)... New York, New York (PRWEB) , ... February 05, 2016 , ... ... in gym use and find themselves having to wait longer to access the treadmills. ... on their New Year’s resolutions to lose weight and get in shape by joining ...
(Date:2/5/2016)... ... February 05, 2016 , ... Pivot Point ... Best in KLAS: Software & Services for HIT Implementation Support & Staffing report ... independently ranks vendor performance by healthcare executives, managers and clinicians representing over 4,500 ...
Breaking Medicine News(10 mins):
(Date:2/5/2016)... , February 5, 2016 ... new market research report "Fetal (Labor & Delivery) and ... Antepartum), Warmer, Incubator, Pulse Oximeter, Phototherapy/Jaundice Management Devices, CPAP, ... by MarketsandMarkets, This report studies the global market over ... is estimated at USD 6.28 Billion in 2015 and ...
(Date:2/4/2016)... 2016 For hospitals considering enrollment in the ... in the program, the Health Resources and Services Administration,s ... , Mega-Guidance , could have significant impact on plans ... September 2016. Essential Insights , Daniel ... summarizes the Mega-Guidance,s key proposed changes, including a new ...
(Date:2/4/2016)... FOSTER CITY, Calif. , Feb. 4, 2016 ... (the "Company") today announced it has entered into ... and Exchange Commission (SEC) fully resolving the SEC,s ... Practices Act (FCPA).  Under the terms of the ... total of $12.8 million, including disgorgement, pre-judgment interest ...
Breaking Medicine Technology: